Botulinum Toxin, Lidocaine, and Dry-Needling Injections in Patients with Myofascial Pain and Headaches

References

• Alvarez JD, Rockwell PG: Trigger points: diagnosis and management. Am Fam Phys 2002; 65:653–660.
   PubMed Web of Science ®Google Scholar
• Aoki KR: Evidence for anti-nociceptive activity of botulinum toxin type A in pain management. Headache 2003; 43:S9–S15.
   Web of Science ®Google Scholar
• Baldry P: Management of myofascial trigger point pain. Acupunture in Medicine 2002; 20:2–10.
   PubMedGoogle Scholar
• Barwood S, et al.: Analgesic effects of botulinum toxin A: a randomized, placebo-controlled clinical trial. Developmental Medicine & Child Neurology 2000; 42:116–121.
   PubMed Web of Science ®Google Scholar
• Behmand RA, Tucker T, Guyuron B: Single-site botulinum toxin type A injection for elimination of migraine trigger points. Headache 2003; 43:1085–1089.
   Web of Science ®Google Scholar
• Dodick DW: Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: from bench to bedside. Headache 2003; 43:S25–S33.
   Web of Science ®Google Scholar
• Fernandez-De-Las-Peñas C, Cuadrado ML, Arendt-Nielsen L, Simons DG, Pareja JA: Myofascial trigger points and sensitization: an updated painmodel for tension-type headache. Cephal 2007; 27:383–393.
   PubMed Web of Science ®Google Scholar
• Frost FA, Jessen B, Siggaard-Andersen, J: A control, double-blind comparison of mepivacaine injection versus saline injection for myofascial pain. Lancet 1980; 1:499–503.
   PubMed Web of Science ®Google Scholar
• Hong CZ: Lidocaine injection versus dry-needling to myofascial trigger point- the importance of the local twitch response. Am J Phys Med Rehabil 1994; 73:256–263.
   PubMed Web of Science ®Google Scholar
• Bernstein RM: Injections and surgical therapy in chronic pain. Clin J Pain 2001; 17:s94–s104.
   Web of Science ®Google Scholar
• Von Lindern JJ, et al.: Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity. J Oral Maxillofac Surg 2003; 61:774–778.
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM: Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders. Headache 2003; 43:853–860.
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM, et al.: Procedures for administering botulinum toxin type A for migraine and tension type headache. Headache 2003; 43:884–891.
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM: Does single-file botox injection really work for primary headache? Headache 2004; 44: 838–839.
   Web of Science ®Google Scholar
• Carlson CH, et al.: Reduction of pain and EMG activity in the masseter region by trapezius trigger point injection. Pain 1993; 55:397–400.
   PubMed Web of Science ®Google Scholar
• Cheshire WP, Abashian SW, Mann JD: Botulinum toxin in the treatment of myofascial pain syndrome. Pain 1994; 59:65–69.
   PubMed Web of Science ®Google Scholar
• Cummings TM, White AR: Needling therapies in the management of myofascial trigger point pain: a systematic review. Arch Phys Med Rehabil 2001; 82:986–992.
   PubMed Web of Science ®Google Scholar
• Garvey TA, Marks MR, Wiesel SW: A prospective, randomized, doubleblind evaluation of trigger-point injection therapy for low-back pain. Spine 1989: 14; 962–964.
   PubMed Web of Science ®Google Scholar
• Iwama H, Akama Y: The superiority of water-diluted 0.25% to neat 1% lidocaine for trigger-point injections in myofascial pain syndrome: a prospective, randomized, double-blinded trial. Anesth Analg 2000; 92:408–409.
   Google Scholar
• Iwama HI, et al.: Water-diluted local anesthetic for trigger-point injection in chronic myofascial pain syndrome: evaluation of types of local anesthetic and concentrations in water. Reg Anesth and Pain Med 2001; 26:333–336.
   PubMed Web of Science ®Google Scholar
• Jenson MG: Reviewing approaches to trigger point decompression. Physician Assist 2002; 26:37–41.
   Google Scholar
• Kamanli A, et al.: Comparison of lidocaine injection, botulinum toxin injection and dry-needling to trigger points in myofascial pain syndrome. Rheumatol Int 2004:15.
   Google Scholar
• Kim P: Role of injection therapy: review of indications for trigger point injections, regional blocks, face joint injections and intra-articular injection. Curr Op Rheumatol 2002; 14:52–57.
   Web of Science ®Google Scholar
• Marica LS, et al.: Chloroprocaine is less painful than lidocaine for skin infiltration anesthesia. Anesth Analg 2002; 94:351–354.
   PubMed Web of Science ®Google Scholar
• McMillan AS, Nolan A, Kelly PJ: The efficacy of dry-needling and procaine in the treatment of myofascial pain in the jaw muscles. J Orofac Pain 1997; 11:307–314.
   PubMedGoogle Scholar
• Porta MA: Comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain 2000; 85:101–105.
   PubMed Web of Science ®Google Scholar
• Porta MA: Treatment of myofascial pain by injection with botulinum toxin: rationale, procedure and outcomes. Adelphi Communications Ltda., Bollington, Macclesfield, Cheshire SK10 5JB, UK, 2003:20.
   Google Scholar
• Tepper SJ, et al.: Botulinum toxin type A in the preventive treatment of refractory headache: a review of 100 consecutive cases. Headache 2004; 44:794–800.
   PubMed Web of Science ®Google Scholar
• Han SC, Harrison P: Myofascial pain syndrome and trigger-point management. Reg Anesth 1997; 22:89–101.
   PubMedGoogle Scholar
• Lang AM: Botulinum toxin type A therapy in chronic pain disorders. Arch Phys Med Rehabil 2003; 84:s69–s73.
   Web of Science ®Google Scholar
• Raphael KG, Marbach JJ, Klausner J: Myofascial face pain clinical characteristics of those with regional vs. widespread pain. J Am Dental Assoc 2000; 131:161–171.
   PubMed Web of Science ®Google Scholar
• Schmitt WJ, et al.: Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double blind, placebo-controlled trial. Headache 2001; 41:658–664.
   PubMed Web of Science ®Google Scholar
• Schwartz M, Freund B: Treatment of temporomandibular disorders with botulinum toxin. Clin J Pain 2002; 18:S198–S203.
   Web of Science ®Google Scholar
• Schulte-Mattler WJ, Krack P: Treatment of chronic tension type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study. Pain 2004:109:110–114.
   PubMed Web of Science ®Google Scholar
• Wheeler AH, Goolkassian P, Gretz SS: A randomized, double blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine 1998; 23:1662–1666.
   PubMed Web of Science ®Google Scholar
• Royal M: The use of botulinum toxins in the management of pain and headache. Pain Practice 2001; 1:215–235.
   Google Scholar
• Dolly OI: Synaptic transmission: inhibition of neurotransmitter release by botulinum toxin. Headache 2003; 43:s16–s24.
   Web of Science ®Google Scholar
• Freund B, Schwartz M, Symington JM: The use of botulinum toxin for the treatment of temporomandibular disorders: preliminary findings. J Oral Maxillofac Surg 1999; 57:916–920.
   PubMed Web of Science ®Google Scholar
• Dodick DW, et al.: Botulinum toxin for the prophylaxis of chronic daily headache: subgroup analysis of patient not receiving another prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 2005; 45:315–324.
   PubMed Web of Science ®Google Scholar
• Evers S, et al.: Botulinum toxin A in the prophylactic treatment of migraine - a randomized, double-blind, placebo-controlled study. Cephal 2004; 24:838–843.
   PubMed Web of Science ®Google Scholar
• Fine PG, Milano R, Hare BD: The effects of myofascial trigger point injections are naloxone reversible. Pain 1988; 32:15–20.
   PubMed Web of Science ®Google Scholar
• Sheean G: Botulinum toxin for the treatment of musculoskeletal pain and spasm. Curr Pain Headache Rep 2002; 6:460–469.
   PubMedGoogle Scholar
• Travell JG, Simons DG: Myofacial pain and dysfunction: the trigger point manual. Baltimore: The Williams and Wilkins Co., 1983.
   Google Scholar
• Lang AM: Botulinum toxin therapy for myofascial pain disorders. Curr Pain Headache Rep 2002; 6:355–360.
   PubMedGoogle Scholar
• Karakurum B, et al.: The dry-needle technique: intramuscular stimulation in tension-type headache. Cephal 2001; 21:813–817.
   PubMed Web of Science ®Google Scholar
• Fishbain DW, et al.: International Headache Society: Headache diagnostic patterns in pain facility patients. Clin J Pain 2001; 17:78–93.
   PubMed Web of Science ®Google Scholar
• Fricton JR: Masticatory myofascial pain: an explanatory model integrating clinical, epidemiological and basic science research. Bull Group Int Rech Sci Stomatol Odontol 1999; 41:14–25.
   PubMedGoogle Scholar
• Guyer B: Mechanism of botulinum toxin in the relief of chronic pain. Curr Rev Pain 1999; 3:427–431.
   PubMedGoogle Scholar
• Niamtu J: Botulinum toxin A: a review of 1,085 oral and maxillofacial patient treatments. J Oral Maxillofac Surg 2003; 61:317–324.
   PubMed Web of Science ®Google Scholar
• Ondo WG, Vuong KD, Derman HS: Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. Cephal 2004; 24:60–65.
   PubMed Web of Science ®Google Scholar
• Raphael KG, et al.: Complementary and alternative therapy use by patients with myofascial temporomandibular disorders. J Orofac Pain 2003; 17:36–41.
   PubMed Web of Science ®Google Scholar
• Fricton JR, Schiffman ES: The craniomandibular index: validity. J Prosthet Dent 1987; 58: 221–228.
   Web of Science ®Google Scholar